STAAR (STAA) Q2 2026 Earnings Call Transcript
STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.
How this was made
The 30-second read
Why it matters
The earnings beat and profit resurgence provide a clear catalyst for short‑term price movement, with upside potential if guidance remains strong.
Market read
First earnings report of the quarter with material profit and revenue growth, making it a high‑impact news item for traders.
What to watch
Potential supply‑chain bottlenecks and ERP implementation risks may affect future quarters.
Background
STAAR Surgical Company reported its Q2 2026 results, showing a turnaround to profitability and significant revenue expansion.
Ticker impact
Q2 2026 earnings release with net sales $93.5M, net income $8.1M and positive adjusted EBITDA, marking a return to profitability.
Potential price rise on the day of release as investors digest the profit turnaround and revenue growth.
First‑time reporting of profit and double‑digit sales growth provides fresh, material information for traders.
Market effects
Highlights growth in the refractive surgery market, especially in China, which may benefit peers.
Strong China performance could lift other ophthalmic device makers with exposure to Asian markets.
Earnings beat adds confidence to the broader medical device sector amid global supply‑chain constraints.
Counterpoint
Margin pressure from China tariffs and currency headwinds could limit upside despite revenue growth.
Key entities
- companySTAAR Surgical Company
Medical device manufacturer specializing in implantable collamer lenses.
- executiveWarren Foust
President and CEO of STAAR Surgical.
